About eMed
eMed is a New York-based telehealth provider offering on-demand clinical trials and chronic care management programs for GLP-1 medications targeting obesity and type 2 diabetes. The platform connects patients with board-certified clinicians via app-based consultations and at-home biometric kits shipped nationwide. eMed partners with Novo Nordisk for Wegovy distribution and ensures 95 percent adherence through remote monitoring.
Founded
2020
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Services, Subscription
Valuation
$2B (Mar 2026)
eMed Valuation
eMed is currently valued at $2B, based on its Series A in March 2026.
The $200M round was led by Aon, with participation from R.J. Melman, Joe Lonsdale, Tom Brady, Antonio Gracias, Tom Ricketts and 3 other investors.
eMed valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Mar 2026 | Series A | $2B |
eMed Funding History
eMed has raised a total of $200M across 1 funding round.
eMed funding rounds
| Date | Stage | Investors | Raised | Valuation |
|---|---|---|---|---|
| Mar 2026 | Series A | Aon (lead); R.J. Melman; Joe Lonsdale; Tom Brady; Antonio Gracias; Tom Ricketts; Ara Cohen; Jeff Aronin; Linda Yaccarino | $200M | $2B |
Who has invested in eMed?
9 investors have backed eMed across its funding rounds, including Aon, Joe Lonsdale, Antonio Gracias, Tom Brady, Ara Cohen and Jeff Aronin.
Lead investors include Aon.
eMed Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 1 | Participant | Mar 2026 | ||
| 1 | Lead | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| -- | 1 | Participant | Mar 2026 | |
This data is available for Pro users. Sign up to see all 9 eMed investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by eMed
eMed has acquired 1 company to date.
Last acquisition by eMed was on January 29th 2024. eMed acquired Science 37 for $38M.
Latest Acquisitions by eMed
| Description | Science 37 is a Los Angeles-headquartered clinical research organization pioneering decentralized and virtual trials. The company operates an integrated platform with telemedicine investigators and home-health nurses, conducting more interventional virtual trials than competitors. Its model accelerates patient enrollment, improves retention rates, and accesses diverse populations unavailable to traditional site-based studies. |
| HQ Country | |
| HQ City | Los Angeles, CA |
| Deal Date | 29 Jan 2024 |
| Valuation | $38M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all eMed acquisitions and their M&A valuation multiples. Start Free Trial | |
eMed Competitors
eMed competitors include listed companies like Guiyang Longmaster and Medley Inc., and private ones like Clarify Health Solutions, Grow Therapy, Cadence Solutions and Assort Health.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $1.4B | - | ||
| Private | $1B | - | $3B | - | ||
| Private | $35M | - | $1.2B | - | ||
| Private | $3M | - | $1.2B | - | ||
| Publicly listed | $44M | $5M | $482M | - | ||
| Publicly listed | $236M | $32M | $459M | 1.8x |
eMed Public Comps
eMed is still privately-owned, but its public comps include Qingdao Baheal Medical, Schrödinger, Ping An Healthcare, Tieto, JMDC, Omnicell, Indegene, Privia Health, EverCommerce and U.S. Physical Therapy.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.1B | $139M | 1.9x | 1.9x | 15.1x | 16.8x | |||
| $256M | ($96M) | 7.6x | 7.9x | (20.3x) | (14.0x) | |||
| $815M | $52M | 0.9x | 0.9x | 13.4x | 16.9x | |||
| $2.1B | $186M | 1.3x | 1.4x | 15.2x | 7.9x | |||
| $324M | $88M | 5.0x | 4.6x | 18.4x | 17.9x | |||
| $1.2B | $92M | 1.2x | 1.1x | 15.0x | 8.1x | |||
| $366M | $68M | 3.7x | 3.3x | 19.9x | 18.2x | |||
| $2.1B | $44M | 1.0x | 0.9x | 50.2x | 15.3x | |||
This data is available for Pro users. Sign up to see all eMed competitors and their valuation data. Start Free Trial | ||||||||
Common questions about eMed
| When was eMed founded? | eMed was founded in 2020. |
| Where is eMed headquartered? | eMed is headquartered in Miami, FL, United States. |
| Is eMed publicly listed? | No, eMed is a private, VC-backed company. |
| What is eMed's valuation? | eMed was last valued at $2B in its Series A in March 2026. |
| How much funding has eMed raised? | eMed has raised $200M across 1 funding round. |
| What was eMed's last funding round? | eMed's last funding round was a $200M Series A in March 2026, led by Aon. |
| Who are eMed's investors? | eMed's investors include R.J. Melman, Aon, Joe Lonsdale, Tom Brady, Antonio Gracias, Tom Ricketts, Ara Cohen, Jeff Aronin and Linda Yaccarino. |
| Which companies are comparable to eMed? | Companies comparable to eMed include Clarify Health Solutions, Grow Therapy, Cadence Solutions, Assort Health, Guiyang Longmaster and Medley Inc.. |
| How many companies has eMed acquired? | eMed has acquired 1 company, including Science 37. |
| What was the largest acquisition by eMed? | The $38M acquisition of Science 37 in January 2024 is the largest acquisition eMed has made to date. |
See companies similar to eMed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




